RAM
CRNX icon

Riggs Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Riggs Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-59
Closed -$1.7K – 295
2025
Q2 		$1.7K Buy
+59
New +$1.82K ﹤0.01% 685
2025
Q1 		– Sell
-34
Closed -$1.72K – 651
2024
Q4 		$1.72K Hold
34
– – ﹤0.01% 386
2024
Q3 		$1.74K Hold
34
– – ﹤0.01% 383
2024
Q2 		$1.52K Hold
34
– – ﹤0.01% 390
2024
Q1 		$1.59K Buy
+34
New +$1.33K ﹤0.01% 373

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Riggs Asset Management's CRNX Position: Q3 2025 in Review

Riggs Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 59 shares — an estimated $1.7K sold.

Riggs Asset Management first reported a position in CRNX in Q1 2024 and held it in 5 quarters. The position peaked at $1.74K in Q3 2024. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Riggs Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Riggs Asset Management sold 59 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $1.7K.
  • Riggs Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Riggs Asset Management's Crinetics Pharmaceuticals position peaked at $1.74K in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.